Sanofi has found yet another partner to help digitize its clinical trial processes. In a statement, TriNetX announced that it will be assisting the pharmaceutical company by using patient EHRs to optimize recruitment, streamline trial investigators’ workflows, and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively.
from MobiHealthNews http://ift.tt/2BlSSVd
January 22, 2018
Rose
MobiHealthNews
No comments
Related Posts:
AI pathology company Paige.AI raises $25M in fundingPaige.AI, a health technology company that applies artificial intelligence to pathology for cancer diagnosis and treatment, recently announced it landed $25 million in Series A funding, led by Jim Breyer of Breyer Capital.&nb… Read More
Calls for Proposals: Precision Medicine Summit, Big Data and Healthcare Analytics Forum, and Healthcare Security ForumHIMSS Media is currently accepting speaking proposals for three events: The HIMSS Precision Medicine Summit in Washington, D.C., the HIMSS Big Data and Healthcare Analytics Forum in San Francisco, and the HIMSS Healthcare Sec… Read More
Medopad gets $28M to connect patients and providers with mobile, AI toolsArtificial intelligence healthcare technology company Medopad has just landed $28 million in a Series A funding round with lead investments from China’s NWS Holdings. But the company announced that its goal is to raise $120 m… Read More
Machine learning in-vitro fertilization company Univfy raises $6MIn-vitro fertilization-focused machine learning company Univfy has raised $6 million in Series A funding, according to a statement released today. The funding round was led by venture firm Rethink Impact, and will b… Read More
Clinical Decision Support Coalition letter criticizes FDA's stance on CDSYesterday the Clinical Decision Support (CDS) Coalition released a comment broadly criticizing the FDA’s recent CDS draft guidance, noting that the draft would expand the scope of FDA regulations, and that it fails to take a … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment